Development of Autoantibody Detecting Kits for Colorectal Cancer in Serum

Colorectal cancer remains the most leading cause of death in Taiwan. The significant burden of illness created by colorectal cancer has encouraged attempts to reduce the mortality rate through earlier detection and treatment. A variety of screening strategies have been proposed in an attempt to interrupt the natural history of colorectal cancer through detecting an early stage, asymptomatic tumors. In previous studies, we have employed a specific tube-gel digestion and LC-MS/MS to predict membrane proteins peculiarly expressed on colorectal cancer. Expression of these proteins was estimated in 8 carcinoma tissues derived from patients with colorectal carcinoma and compared with same normal tissues derived from the corresponding sites of tumor origin. Of 649 membrane proteins identified as expressed in cancer tissues. We choose three of the candidate membrane proteins with high levels of tumor-associated expression by MS/MS analyses and further clone and express the recombinant membrane proteins, including Claudin-3(CLDN3), Annexin IV(ANXA4), and defensin 1(DEFA1). These recombinant proteins would be developed an immunoassay with a multiple antigen panel of 3 above-mentioned membrane proteins in clinical screening of patient’s serum. The assay could detect antibody against specific membrane proteins from cancer patient serum and might contribute a clinically useful non-invasive approach to cancer detection and diagnosis.

Project ID:PC9907-1941
External Project ID:NSC99-2622-B182-001-CC3